Nothing Special   »   [go: up one dir, main page]

WO2014106804A3 - Compositions and methods for the treatment of metabolic syndrome and diabetes - Google Patents

Compositions and methods for the treatment of metabolic syndrome and diabetes Download PDF

Info

Publication number
WO2014106804A3
WO2014106804A3 PCT/IB2013/061384 IB2013061384W WO2014106804A3 WO 2014106804 A3 WO2014106804 A3 WO 2014106804A3 IB 2013061384 W IB2013061384 W IB 2013061384W WO 2014106804 A3 WO2014106804 A3 WO 2014106804A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compositions
diabetes
treatment
methods
Prior art date
Application number
PCT/IB2013/061384
Other languages
French (fr)
Other versions
WO2014106804A2 (en
Inventor
Mahesh Kandula
Original Assignee
Cellixbio Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellixbio Private Limited filed Critical Cellixbio Private Limited
Publication of WO2014106804A2 publication Critical patent/WO2014106804A2/en
Publication of WO2014106804A3 publication Critical patent/WO2014106804A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing metabolic syndrome and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, neuropathic pain, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.
PCT/IB2013/061384 2013-01-04 2013-12-28 Compositions and methods for the treatment of metabolic syndrome and diabetes WO2014106804A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN52/CHE/2013 2013-01-04
IN52CH2013 2013-01-04

Publications (2)

Publication Number Publication Date
WO2014106804A2 WO2014106804A2 (en) 2014-07-10
WO2014106804A3 true WO2014106804A3 (en) 2017-04-13

Family

ID=51062520

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/061384 WO2014106804A2 (en) 2013-01-04 2013-12-28 Compositions and methods for the treatment of metabolic syndrome and diabetes

Country Status (1)

Country Link
WO (1) WO2014106804A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7208982B2 (en) 2017-09-20 2023-01-19 チオジェネシス セラピューティクス， インコーポレイテッド Methods of Treating Cysteamine Sensitive Disorders
JP7418958B2 (en) 2016-03-17 2024-01-22 チオジェネシス セラピューティクス， インコーポレイテッド Compositions for controlled release of cysteamine and systemic treatment of cysteamine-sensitive disorders

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106883158B (en) * 2015-12-15 2019-08-23 中国科学院广州生物医药与健康研究院 Biodegradable amino lipids class compound and its preparation method and application

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0131995A1 (en) * 1983-07-19 1985-01-23 Maggioni-Winthrop S.P.A. Compounds with hypolipemic activity
US5120738A (en) * 1989-10-06 1992-06-09 Fujirebio Inc. Pantothenic acid derivatives
WO1995011673A1 (en) * 1993-10-27 1995-05-04 Oculon Corporation Compounds and methods for treating sickle cell anemia
US20010002404A1 (en) * 1996-05-22 2001-05-31 Webb Nigel L. Fatty acid-pharmaceutical agent conjugates
US20100184730A1 (en) * 2008-07-08 2010-07-22 Vu Chi B Fatty Acid Acylated Salicylates and Their Uses
WO2011106688A1 (en) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
US20120184585A1 (en) * 2009-09-01 2012-07-19 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
WO2012149352A1 (en) * 2011-04-29 2012-11-01 Catabasis Pharmaceuticals, Inc. Fatty acid guanidine and salicylate guanidine derivatives and their uses
WO2014087307A2 (en) * 2012-12-04 2014-06-12 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome and diabetes

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0131995A1 (en) * 1983-07-19 1985-01-23 Maggioni-Winthrop S.P.A. Compounds with hypolipemic activity
US5120738A (en) * 1989-10-06 1992-06-09 Fujirebio Inc. Pantothenic acid derivatives
WO1995011673A1 (en) * 1993-10-27 1995-05-04 Oculon Corporation Compounds and methods for treating sickle cell anemia
US20010002404A1 (en) * 1996-05-22 2001-05-31 Webb Nigel L. Fatty acid-pharmaceutical agent conjugates
US20100184730A1 (en) * 2008-07-08 2010-07-22 Vu Chi B Fatty Acid Acylated Salicylates and Their Uses
US20120184585A1 (en) * 2009-09-01 2012-07-19 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
WO2011106688A1 (en) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
WO2012149352A1 (en) * 2011-04-29 2012-11-01 Catabasis Pharmaceuticals, Inc. Fatty acid guanidine and salicylate guanidine derivatives and their uses
WO2014087307A2 (en) * 2012-12-04 2014-06-12 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome and diabetes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7418958B2 (en) 2016-03-17 2024-01-22 チオジェネシス セラピューティクス， インコーポレイテッド Compositions for controlled release of cysteamine and systemic treatment of cysteamine-sensitive disorders
JP7208982B2 (en) 2017-09-20 2023-01-19 チオジェネシス セラピューティクス， インコーポレイテッド Methods of Treating Cysteamine Sensitive Disorders

Also Published As

Publication number Publication date
WO2014106804A2 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
WO2014087307A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2013175377A3 (en) Compositions and methods for treatment of mucositis
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
MX2019007713A (en) Compositions and methods for the treatment of chronic pain.
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
WO2014174425A3 (en) Compositions and methods for the treatment of orthostasis and neurological diseases
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis
WO2014106804A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
WO2014080307A3 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
WO2014006529A3 (en) Compositions and methods for the treatment of moderate to severe pain
WO2014195810A3 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
WO2013167998A3 (en) Compositions and methods for the treatment of autonomic and other neurological disorders
WO2014195850A3 (en) Compositions and methods for the treatment of neurologic diseases and neurological disorders
WO2014097137A3 (en) Compositions and methods for the treatment of seizures and neurologic diseases
WO2013175344A3 (en) Compositions and methods for treatment of peridontitis and rheumatoid arthritis
MX2019005568A (en) Compositions and methods for the treatment of gastrointestinal polyps.
WO2014083476A3 (en) Compositions and methods for the treatment of metabolic and lipid disorders
WO2014068459A3 (en) Compositions and methods for the treatment of pain and neurological diseases
WO2014106805A3 (en) Fatty acid conjugates and their uses
WO2015015403A3 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
WO2014068461A3 (en) Compositions and methods for the treatment of acute inflammation

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13870022

Country of ref document: EP

Kind code of ref document: A2